Skip to main content

Table 2 The Most Common Patients’ Clinical Status on Study Days 1, 3, 7, and 14

From: Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial

Clinical Presentation Placebo/Routine Care Levamisole/ Routine Care P value
N (%) N (%)
Fever
 Day 1 20 (80.0) 24 (96.0) 0.189
 Day 3 20 (80.0) 24 (96.0) 0.189
 Day 7 3 (12.0) 0 (0.0) 0.235
 Day 14 0 (0.0) 0 (0.0) 1.000
Cough
 Day 1 17 (68.0) 22 (88.0) 0.088
 Day 3 17 (68.0) 23 (92.0) 0.034
 Day 7 17 (68.0) 15 (60.0) 0.556
 Day 14 9 (36.0) 1 (4.0) 0.005
Dyspnea
 Day 1 13 (52.0) 14 (56.0) 0.777
 Day 3 13 (52.0) 14 (56.0) 0.777
 Day 7 12 (48.0) 4 (16.0) 0.015
 Day 14 0 (0.0) 7 (28.0) 0.010
Asthenia
 Day 1 5 (20.0) 4 (16.0) 0.490
 Day 3 5 (20.0) 2 (8.0) 0.235
 Day 7 4 (16.0) 1 (4.0) 0.235
 Day 14 3 (12.0) 0 (0.0) 0.235
Headache
 Day 1 2 (8.0) 2 (8.0) 1.000
 Day 3 2 (8.0) 2 (8.0) 1.000
 Day 7 1 (4.0) 0 (0.0) 1.000
 Day 14 1 (4.0) 0 (0.0) 1.000
Dizziness
 Day 1 2 (8.0) 1 (4.0) 1.000
 Day 3 2 (8.0) 1 (4.0) 1.000
 Day 7 2 (8.0) 0 (0.0) 0.490
 Day 14 2 (8.0) 0 (0.0) 0.490
Myalgia
 Day 1 3 (12.0) 2 (8.0) 0.235
 Day 3 3 (12.0) 2 (8.0) 0.235
 Day 7 3 (12.0) 0 (0.0) 0.235
 Day 14 2 (8.0) 0 (0.0) 0.490
Nausea
 Day 1 2 (8.0) 1 (4.0) 1.000
 Day 3 2 (8.0) 1 (4.0) 1.000
 Day 7 1 (4.0) 1 (4.0) 1.000
 Day 14 1 (4.0) 0 (0.0) 1.000